Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. - Wikidata - awgldk - TriplyDB

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

http://www.wikidata.org/entity/Q33602588

about

The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review.PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson's disease: evidence for dopaminergic basis?Salience and Default Mode Network Coupling Predicts Cognition in Aging and Parkinson's Disease.A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease Why psychosis is frequently associated with Parkinson's disease?Altered intrinsic functional coupling between core neurocognitive networks in Parkinson's disease.Cognition in movement disorders: where can we hope to be in ten years?Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype.Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.Heterogeneity of Monosymptomatic Resting Tremor in a Prospective Study: Clinical Features, Electrophysiological Test, and Dopamine Transporter Positron Emission Tomography.Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.Biomarkers in Parkinson's disease: Advances and strategies.Neuroprotective Effects of Jitai Tablet, a Traditional Chinese Medicine, on the MPTP-Induced Acute Model of Parkinson's Disease: Involvement of the Dopamine System.Recent developments in biomarkers in Parkinson disease A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.A Comprehensive View of the Neurotoxicity Mechanisms of Cocaine and Ethanol.The psychosis spectrum in Parkinson disease.Progression of subcortical atrophy in mild Parkinson's disease and its impact on cognition.Biomarkers in Prodromal Parkinson Disease: a Qualitative Review.Biomarkers in Neurodegenerative Diseases.Cognitive decline in Parkinson's disease: the complex picture.Reply: Unusual DAT scan results.Many roads lead to Parkinson's disease.Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.Unusual DaTscan results.Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease.Predicting progression in patients with Parkinson's disease.Uric acid relates to dopamine transporter availability in Parkinson's disease.Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.

P2860

Q30635471-1C40E36C-B60C-47B9-AC78-5546AA4C0CCC Q33637285-C0E037BF-D384-4761-B1B1-35C1F7EC74AF Q33698810-29EBB4F5-F404-4D74-8F5B-6F097B6D830F Q33731267-702B67DF-C32D-4ECB-BB42-AA8BBB6F874D Q33787942-48BEB521-60B1-4275-AD42-CBEF4D00912C Q33788172-7EE8CA5E-D647-4691-B30F-BA60E67646EA Q34094668-0DEDC484-9AA0-4733-883C-3369925EBC45 Q35059334-ABF7A6E8-99D1-4B65-B59F-39656EB787A7 Q35211553-0452166E-00B4-4052-8DBF-92C2011FA0E1 Q36271585-B0EB3738-5E61-47B5-B0ED-D7C5885BDBB1 Q36328177-3CAC5818-B244-48C9-8D87-9DE699FA0CCC Q36351574-5579273A-20CD-4786-A68E-D23774080757 Q36523068-5EC06185-4738-4953-AAAE-FB70E306BA6E Q36785957-0A2D9938-33AF-4451-8B63-C9530E58BF4E Q37431507-9AA1A71C-1467-4B74-B1B0-8B02E573B1AD Q37718841-6EAB683A-A132-4C6C-A76B-30108340D12D Q38119095-5D56B48B-FE59-4281-AEDD-E77C8FE16E52 Q38187007-F1A674F6-9442-45F3-A179-7A0CD7509D0C Q38536415-C161F6CC-1337-4F42-A682-F870779C1E27 Q38768169-3E18018A-8118-42B3-B65E-1708FDC26DB5 Q38784016-38800774-7BB0-46D3-B449-AC88FE0C59FF Q38788917-999E444D-38EC-460B-A611-EEC93F606DFE Q39413097-5F973C91-C48F-4669-A204-04509A79B618 Q39446566-45E4340C-CAEB-439F-BBEA-40875983FC78 Q44328164-CF6CFFCE-3774-405A-832F-C070FC304882 Q44970760-225C34D4-9CBF-4D28-957B-94DBE8C5223E Q45945368-9A2F43A5-5FD4-4F0F-A6D3-B80D5D299C2F Q46791804-B1C21C03-FD82-4DCE-BD0C-24EE37BC2A9B Q48129130-1A67F9C3-9FDB-4431-ACCF-D637B77E9EFA Q48142962-11D19ABB-CE39-4C9F-9768-6E5E343BB6D3 Q48492369-18DB373A-F449-4AA5-81D8-322665D61D7B Q48496079-75DF68B4-722F-423E-885B-4C82EDBBE257 Q49136792-06DF208E-D981-423B-9E2D-3586311EE224 Q49663221-F92D6CB7-FECB-4012-87D1-432B266E4851 Q50607607-C5F69A4A-04F8-4830-AE97-597B72D03FD6 Q51583546-5CADE4CD-9E4E-4A87-B59B-A4B14773EA77

P2860

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

http://www.wikidata.org/entity/Q33602588

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@ast

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@en

type

label

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@ast

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@en

prefLabel

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@ast

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@en

P1433

Q33602588-B91E17AE-8410-4C50-AEA0-ED407F1E6E8D

P1476

Q33602588-03D7CBD3-5037-49E3-9879-FB544B7DAAC8

P2093

Q33602588-20FF2B75-01BD-474B-B3D4-C95AE58072EB

Q33602588-69DD8473-AACC-44F5-B320-F98C7880EA20

Q33602588-7EDE15E8-B161-4A72-9F0E-BC30AFC33C23

Q33602588-8C001F13-03E8-4178-B24E-9C88ACD28A7F

Q33602588-9259EB58-793E-4DED-87ED-455D72A39CD5

Q33602588-9FCB76CB-BE59-42DF-9BA2-1DDE7AD406DB

Q33602588-A7432407-33AB-46EF-A039-695A02AE83D5

Q33602588-B08C412F-7B27-4E8D-980E-3643339679C0

Q33602588-B7B6FD31-7E48-4680-B5D7-BB8D31773E4C

Q33602588-C6E58267-8288-463F-98DD-CB726236946A

P2860

Q33602588-0C74BF19-35D4-43EB-AAC5-5AD1D6DEA84C

Q33602588-1A3C3FEE-7C95-4FE0-B514-C279C97C9072

Q33602588-1F9ECE8C-3286-4A39-86A0-6BD68B239C68

Q33602588-1FF43521-DCD1-4A6A-BB34-34B9358C1E08

Q33602588-328F31DF-4392-4546-BCF1-4AB32DA9DAB9

Q33602588-32B5EF88-E303-48F8-9A0E-B325CFE34E2E

Q33602588-435F0555-705E-42D1-8E67-605E92B1D378

Q33602588-4E8A7A4C-5CD8-4FC5-8960-3D1E2F50C08F

Q33602588-50F12B0F-DCDA-4161-8402-7BD36DA418DA

Q33602588-5BF9BDEE-48CA-4324-BB9E-B6FD8724A176

P304

Q33602588-F65CEEA2-79E6-4711-B58A-88E3EA209585

P31

Q33602588-974CAD72-EA7B-419B-AE16-E185F5AA317E

P356

Q33602588-D14D8216-48AA-4138-A797-86178D34725C

P407

Q33602588-B1675804-3270-4BF7-9446-DE124D205C1C

P433

Q33602588-0C13DF8B-3C19-4893-92E1-D5A03AD6B3E2

P478

Q33602588-5E05178E-ABB2-48E4-A0A3-DCDE883BD441

P50

Q33602588-2ACB52EC-56E2-4334-8DA9-B17D14F1AB8A

Q33602588-AD868DB1-7775-4B4D-A171-033D48172C52

Q33602588-C356DE85-4948-40BD-BACF-D70174CC9276

Q33602588-D5AB6A37-AD3A-401C-BD3B-406C4FE7B3EE

Q33602588-FCB7AC63-BB06-4AED-AD28-CA6A87100F65

P577

Q33602588-A47D5B83-2BE0-4CAB-9391-A9D85639C2E7

P698

Q33602588-13CF6B2C-3779-4E60-B6F5-A8C7B31E37D8

P921

Q33602588-76b30a81-7f98-47d1-b762-83b52522ed4e

Q33602588-D7FE320D-9B0B-47B7-8AB7-C12116CFA10B

P932

Q33602588-3EBC986B-4555-46E3-A7D6-FC0E296D17E2

P356

P1433

Movement Disorders

P1476

Dopamine transporter imaging i ...... tcomes in Parkinson's disease.

@en

P2093

Bernard Ravina

http://www.w3.org/2001/XMLSchema#string

David Oakes

http://www.w3.org/2001/XMLSchema#string

Emily Flagg

http://www.w3.org/2001/XMLSchema#string

Flint Beal

http://www.w3.org/2001/XMLSchema#string

Ira Shoulson

http://www.w3.org/2001/XMLSchema#string

Jennifer Harman

http://www.w3.org/2001/XMLSchema#string

Kenneth Marek

http://www.w3.org/2001/XMLSchema#string

Roger Kurlan

http://www.w3.org/2001/XMLSchema#string

Shirley Eberly

http://www.w3.org/2001/XMLSchema#string

Wendy R Galpern

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinsonism: onset, progression and mortality

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

Dopamine, learning and motivation

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

Levodopa and the progression of Parkinson's disease.

Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease

The role of radiotracer imaging in Parkinson disease.

Functional neuroanatomical double dissociation of mnemonic and executive control processes contributing to working memory performance.

Role of dopamine in the motivational and cognitive control of behavior.

P304

1392-1397

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.25157

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Caroline M Tanner

Michael A Schwarzschild

Alberto Ascherio

P577

2012-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22976926

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

5404810

http://www.w3.org/2001/XMLSchema#string